Member Info for dallo

Lambo

The AIM market is the wild West at the moment with most companies struggling to get funding and being totally ignored by investors particularly minnows like Immupharma whose historic performance has been dreadful.

However the company is on the cusp of being a serious player with its late stage drug therapies and should the Avion commitment be confirmed and trial dates confirmed the share price could rerate sharply.

If a Rest of the World deal on Lupuzor or anything on CIPD be announced it would be even better.

I have an investment in Ethernity Networks of a similar amount to Immupharma which was awful until this week a rerating took place and the shares surged over 2 days by a staggering 1600% at one stage yesterday with some profit taking today.

The volumes traded were twice the issued shares as the punters piled in.

I am not saying for one minute that this will happen in Immupharma's case but it illustrates how beaten down AIM stocks can bolt ahead if the herd smells something.

Dream on you rightly say but Immupharma will rerate substantially on some good news imho.

Lambo

Let's assume Alora/Avion walk after exhaustive consultations with the FDA which resulted in a comprehensive set of guidelines and parameters in relation to the Phase 2/3 Lupuzor trials and after Alora

invested c£1.1 m directly in Immupharma and thereby relinquish its rights to North American Market for Lupuzor.

Then Immupharma would be free to discuss a deal with a large Pharma for the total worldwide rights for Lupuzor and for CIPD.

Immupharma may also then be an attractive takeover target given its tiny market cap of c£6m.

I don't think Art Deas has come this far to walk away but it is possible but would not be fatal for Immupharma imho.

If Alora/Avion has walked Immupharma must issue a RNS asap and so far we haven't seen one.

I agree the silence is extremely unsettling but as someone who has been here for 8 years, I am used to it.

Nolupus

No

Alora Pharma Group only mentions drugs and therapies it actually sells and distributes not a drug which has yet to be approved or in clinical trials.

I hope that is of assistance to you.

Also as a private company it has no regulatory or other

requirement to say anything to anyone.

Cheers

Just to add that the Alora Group has 90 + drug therapies on the market at present in 7 major therapeutics.

The Alora new website has only come on stream in the past 2 months.

I urge investors to access it now.

Oscar

I will not go through again my previous detailed analysis of the Alora Pharma Group other than to advise investors to go the updated Alora website to get a full picture of this growing private Pharmaceuticals enterprise with 5 major subsidiary companies including Avion Pharma who in 2022 got FDA approval for Dhivy a drug to treat Parkinsons Disease.

The Alora Group headed by Art Deas with 5 manufacturing and research facilities mainly based in Georgia, USA with 600 employees and a large range

of diverse drugs and therapies is possibly valued at over $1billion.

It's acquisition of Osmotica's manufacturing facilities

and drug therapies for over $200m in 2022 was a big statement.

I agree with you that Lupuzor is a big deal for Art Deas for relatively small money and he has gone so far now he will see this through.

The AIM market is a hellhole for investors at the moment but Immupharma could be a absolute gem in the manure .

Dyor

Atb

Oscar

Many thanks for your usual well informed and intelligent posts.

It is appreciated.

The markets are awful at the moment with the Israeli horror show adding more concern and trepidation.

Provided there is no serious escalation the markets will adjust. If there is a World War 3 then Immupharma will be the least of our worries.

Also if the Alora/Avion deal, which is a legal commitment signed by both parties, is in dispute or difficulty then Immupharma must notify the market immediately.

Even if Art Deas walks, there will plenty more interest from other Pharmas given the extensive consultation with the FDA on the trial parameters and the FDA 's subsequent guidance.

We are still in the game imho.

Maidit

Thanks for that.

Now let's see can Uncle Tim deliver on the rhetoric.

Cheers

LearningG

Thank you for your vote of confidence in me being Chairman of Ethernity.

However some would question my judgement in building up a large stake in the first place and not selling at a large profit when the SP hit 55/60p ( albeit briefly) and they would be correct with the benefit of hindsight.

However hindsight is wonderful but a lot happened subsequent to my initial investments in Ethernity in 2019/20 with the total pandemic lockdowns in Israel in

particular , hundreds of Hamas rockets landing in Lot close to Ethernity old HQ, followed by the Ukraine war , major chip shortages and delays in 5G and other telecom infrastructure investment and the crash in Technology companies share prices in 2022 et al.

Don't get me wrong Ethernity management and the Board made some horrible mistakes with over optimistic forecasts, bad financial management , major R&D spend on new products and IP linked to misguided contracts with OEMs which were totally dependent on successful deployment of the OEMs roll outs and leaving Ethernity exposed to cancellations, delays and in some cases non payment etc.

They have expended cash and resources in product development and now are cash strapped as it changes back to a licencing model .

It appears too late but I have proposed possible solutions to David Levi involving an angel investor using a Senior Unsecured Convertible Loan Note structure and an amendment to the Subscription Agreement whereby the new investor and Bergen could exercise their respective rights at the warrants price of 6p and perhaps give the Convertible Loan Note holder warrants on a 1 to 1 basis on the amount of the Note.

I am proposing a CLN of c$1m Convertible at 6p with a coupon of say 5% ranking ahead of the equity and a similar amount in warrants.

This is a deal that could sort Bergen out , get cash in now and warrants cash subsequently.

However I suspect Ethernity need to show new contracts before such a deal can be done and get the SP back to 3/5p.

It is possible but a may be very late in the day.

There are 30 + billionaires in Israel and surely Levi/ Yosi and the other Israeli Directors have still some friends.

At the moment all is lost but there are solutions I hope

01234

Sorry about that .

Why can't posters keep it simple like just have one three letter name like Bob.

RNS not concerning, I should say

01234

I don't think I was positive just a massive exhalation of relief that the RNS was concerning liquidation, delisting, Directors resignations etc.

Ethernity has still to perform a minor miracle if it is to survive and has just 3/4 months to do so.

Cash position is the key consideration now for both customers and investors.

Ethernity has been working with Raytheon Technologies on the aviation switch software deal for over 4 years and finally the US Government has approved Raytheon to deal with Ethernity.

That is a very attractive piece of US Government approved business and indeed could be important to an acquirer not to mention Ethernity's near $40m in tax losses.

Another possible gold nugget in the manure is the confirmation that the US Government has approved the US Tier 1 military giant ( which Levy already mentioned previously as Raytheon Technologies) to work with Ethernity on a longstanding aviation software product deal.

This could be significant IF it comes to fruition.

It looks like the SP is stable after results and may even go higher during the day.

A big few weeks ahead but not in liquidation yet!

I will review Interims in detail later but , given that I thought the company was going to go bust this week , I now feel it has a fighting chance .

The key is the next few weeks to see whether there is any positive newsflow.

If not then we are in trouble.

ATB

And Ethernity received the last cash tranche of 60% of the Tarana order of $1.5m I.e. $900,000 two weeks ago.

Not as bad as I was expecting but Ethernity still need licencing contracts ASAP to generate the cash flow to get to EBITDA positive for 2nd half.

Not dead yet but we need a major boost from somewhere.

Skid

Not to mention the Indian contract which Levi said would grow to 10s of millions of $ in revenue at our meeting in London and was never heard of again.

There were so other many false statements and forecasts made since 2020 , non of which ever materialised.

Even the burger van revenues reported were not real with most ending up in debtors or written off.

It was a fantasy business with nothing ever produced that anyone ever wanted apart from low tech stuff supplied to Tarana who themselves are struggling to produce revenues of any substance.

Sad denouement for us all after a long 4/5 years of believing in this gang of chancers.

Joe

All the investors in Ethernity have been destroyed by this bunch of incompetent fantasists and all the blame rests on Levi and a utterly pathetic Board of Directors.

There is no fool like a old fool and that's how I feel today.

We all could have got out at a profit when the SP was in the 50p plus range but sadly I got too close to the company as a large shareholder and believed the hype and the fact that Levi was putting significant investment in himself at every placing

At a market cap of just £1.5m it is effectively worthless now but surely with tax losses of c$40m plus million, patents, Tarana contract and IP , it must be worth something more than £1.5m.

The Catch 22 I alluded to regarding the fall in the SP giving Bergen an ever increasing % of the company is now happening and maybe Bergen should call all shares now at 1p and get c50% of the company and sell it .

But then again Bergen is a mysterious outfit who we have no idea what it's current status is.

Bar a miracle it looks like the endgame is approaching.

I share everyone's pain.

ATB

Nolupus

I was wondering when you would come out of your lair and start spewing your usual critical analysis of what others had opined.

Firstly I suggested that on the SUCCESSFUL conclusion of the Lupuzor trial , Alora MAY be tempted to take out Immupharma.

As you rightly know there is a long way to go before the trial results so obviously no incentive to take out Immupharma at the moment particularly when you are risking c$25m on a trial.

The fact that at 1.8p , I have obviously been wrong but since you never bought one share in Immupharma, you are right.

Well done but why have you been on this chat board for 6 years with the same old smarmy self righteous posts?.

Anyway enjoy your weekend you smug ....

Older

The Alora Group has made huge progress in the past 3 years ,following the acquisition of Osmotica's legacy businesses which included 2 manufacturing plants in Georgia and a portfolio of drugs

The Alora group now has diversified suite of medicines including it's traditional women's therapies and drugs.

It now has acquired and developed drugs and medicines in areas such as Endocrinology, Neurology, Parkinsons and others.

The Group now comprises Avion , Acella , Sovereign, Vertical, Trigen Labs and Osmotica and has beefed up its Board and management.

Even its website has improved immeasurably in the past year and the valuation of the Group could increase as the 2 year slump in US Pharma companies share prices looks like coming to an end.

The website doesn't mention Immupharma as Art Deas is a very private individual who will only focus on positive factual information and not on nearly stage projects imho.

However a successful Lupuzor trial could be the catalyst for an IPO and may prompt Alora to take out Immupharma.

Hence my comments on Lanstead who with 22% of the shares in Immupharma, are in a very strong position to deal with Art Deas whilst management in Immupharma hold a tiny amount of shares .

We could all do with a bit of good news soon

It has been a long ardous journey for me and others here .

ATB

Shares getting a nice rerate as the FDA decision on Karuna's KarTX drug for schizophrenia is imminent probably followed by a big special dividend to Puretech shareholders.

If all goes well we could see the SP push past £3 in the coming weeks

ATB